Auxo Firm Directory · Independent Research Profile

Deerfield

Deerfield Management Company, L.P. is a healthcare investment firm launched in 1994 and headquartered in New York. Its stated interests include therapeutics, medical devices, healthcare services, diagnostics, and digital health, with investments ranging from early-stage startups to mature private or public companies.

Key takeaway

What stands out about Deerfield

Deerfield publicly describes a flexible healthcare investment model spanning venture, growth, debt and equity, strategic partnerships, and support across the company lifecycle. Owners should clarify the investing entity or fund, proposed instrument, governance terms, expected investment horizon, follow-on capital, and available operating or scientific resources.[1][2][3][5][9][11]

What does Deerfield invest in?

Deerfield Management Company, L.P. is an investment firm launched in 1994 and headquartered at 345 Park Avenue South, New York, NY 10010. Deerfield states that it supports companies across the healthcare ecosystem with flexible financing and investment across the capital structure, from early-stage startup through mature private or public company.

As of December 31, 2025, Deerfield states that it manages more than $16 billion in assets, has more than 200 private and public investments, and has more than 180 team members, including 60+ MDs, JDs, and PhDs.[1][2]

Deerfield describes a flexible investment approach that spans the capital structure and company lifecycle. Its stated interests include therapeutics, medical devices, healthcare services, diagnostics, and digital health.

The firm also describes providing capital, scientific expertise, business and operational support, and access to innovation through strategic partnerships with healthcare companies and research institutions.[2][3]

Owners comparing capital alternatives can review Auxo’s capital advisory services, valuation services, and full-versus-partial sale framework.

Public size / criteria information
As of December 31, 2025, Deerfield states that it manages more than $16 billion in assets, has more than 200 private and public investments, and has more than 180 team members, including 60+ MDs, JDs, and PhDs. It invests from early-stage startup through mature private or public company and across the capital structure.[2][9]

What should a business owner evaluate before taking capital from Deerfield?

For a healthcare company owner or founder, Deerfield’s published model includes sector-specific capital, flexible financing, scientific expertise, business and operational support, and strategic partnerships. An owner evaluating the firm should clarify which legal entity, fund, or affiliate would invest; the proposed instrument and capital structure; ownership, governance, board, consent, and information rights; the expected investment horizon and exit approach; available follow-on capital; and the Deerfield resources that would be available. Fund-level valuation, fee, governance, ownership, and exit terms are not published on Deerfield’s Terms of Use page.[2][3][11]

01

Which Deerfield legal entity, fund, or affiliate would make the investment

Deerfield describes a multi-faceted investment model, while its Terms of Use states that advisory services are provided to a limited number of private investment vehicles rather than the public.[11]
02

What instrument and capital structure are contemplated

Deerfield states that it invests across the capital structure, and its portfolio disclosures include both equity financing and debt-and-equity growth financing.[2][4][6]
03

What ownership, governance, board, consent, and information rights would apply

Deerfield’s Terms of Use does not publish fund-level governance or ownership terms for its private investment vehicles.[11]

What investment criteria does Deerfield publicly describe?

Deerfield identifies healthcare companies across therapeutics, medical technologies, healthcare services, diagnostics, and digital health. Its stated lifecycle range extends from early-stage startups to mature private or public companies.

Examples in Deerfield’s official portfolio include Boulevard Bio, a therapeutics venture investment listed with an August 2026 transaction date and seed/startup stage; Deerfield Catalyst, a medical-technologies venture investment listed with a January 2021 transaction date and seed/startup stage; and Endologix, which the portfolio page states is wholly owned by Deerfield Management and received initial growth financing structured as debt and equity in April 2017.[2][4][5][6]

Deerfield’s stated interests include healthcare sectors, a lifecycle range from early-stage startup to mature private or public company, and investment across the capital structure.[2]

Deerfield identifies its headquarters as 345 Park Avenue South, New York, NY 10010. Deerfield’s official investment page does not state a universal geographic investment mandate.[2][12]

Selected official portfolio disclosures include Boulevard Bio in therapeutics, Deerfield Catalyst in medical technologies, and Endologix. Boulevard Bio is listed as an August 2026 seed/startup venture investment with an equity financing structure. Deerfield Catalyst is listed as a January 2021 seed/startup venture investment with an equity financing structure. The Endologix page states that the company is wholly owned by Deerfield Management and identifies its initial April 2017 transaction as growth financing structured as debt and equity.[4][5][6]

On June 10, 2026, Deerfield announced that portfolio company Nuvalent, Inc. would be acquired by GSK. On September 5, 2025, Deerfield announced the sale of Melinta Therapeutics. On May 5, 2025, Deerfield announced the closing of Healthcare Innovations Fund III with more than $600 million; the fund was described as targeting therapeutics, improvements to healthcare delivery, and paradigm-shifting technologies.[7][8][9]

What is not clear from Deerfield's public materials?

The Deerfield Catalyst portfolio page does not disclose transaction valuation, ownership percentage, or financing amount for the January 2021 equity transaction.

Deerfield’s official investment page does not state a standardized investment holding-period range or a universal geographic investment mandate. Deerfield’s Terms of Use does not publish fund-level valuation, fee, governance, ownership, or exit terms for its private investment vehicles.[2][5][11]

Questions to ask before taking capital from Deerfield

Which Deerfield legal entity, fund, or affiliate would make the investment?
Deerfield describes a multi-faceted investment model, while its Terms of Use states that advisory services are provided to a limited number of private investment vehicles rather than the public.[11]
What instrument and capital structure are contemplated?
Deerfield states that it invests across the capital structure, and its portfolio disclosures include both equity financing and debt-and-equity growth financing.[2][4][6]
What ownership, governance, board, consent, and information rights would apply?
Deerfield’s Terms of Use does not publish fund-level governance or ownership terms for its private investment vehicles.[11]
What is the expected investment horizon and exit approach?
Deerfield’s official investment page does not state a standardized investment holding-period range.[2]
How much follow-on capital is available?
Deerfield describes investing across company stages and the capital structure; the availability of follow-on capital is a diligence point to clarify.[2]
Which Deerfield operating, scientific, market-research, or portfolio-company resources would be available?
Deerfield publicly describes scientific, business, and operational support, as well as access to innovation through strategic partnerships.[3]
What valuation, fees, expenses, liquidation preferences, covenants, or other economic terms would apply?
Deerfield’s Terms of Use does not publish fund-level valuation or fee terms for its private investment vehicles, and the Deerfield Catalyst portfolio page does not disclose transaction valuation or financing amount.[5][11]
Can Deerfield provide references from healthcare transactions?
Deerfield publicly identifies healthcare investments and transactions across therapeutics, medical technologies, and other healthcare categories, including Boulevard Bio, Deerfield Catalyst, Endologix, Nuvalent, and Melinta Therapeutics.[2][4][5][6][7][8]

Sources & research notes

Public-source research
  1. Official website / firm overview
  2. Services / capabilities
  3. Investment approach
  4. Transaction / portfolio evidence
  5. Transaction / portfolio evidence
  6. Transaction / portfolio evidence
  7. Transaction / portfolio evidence
  8. Transaction / portfolio evidence
  9. Transaction size / criteria
  10. SEC investment adviser record
  11. Structure / regulatory context
  12. Geography / market coverage
Prepared and reviewed by: Auxo Capital AdvisorsEvidence standard: Public-source verification

How this profile was researched

Auxo profiles are prepared from publicly available primary and authoritative sources and reviewed for entity identity, factual support and disclosure consistency. When a fact cannot be supported by the reviewed public record, the profile identifies it as something to confirm directly rather than inferring it.

Independent profile & regulatory context

Independent research profile

This profile was prepared by Auxo Capital Advisors from publicly available information believed to be reliable and is provided solely for informational and educational purposes. It is not an endorsement, recommendation, ranking, solicitation, or representation regarding the profiled firm, its services, qualifications, transaction experience, regulatory status, financial condition, or suitability for any particular person, company, transaction, or investment.

Information obtained from third-party and public sources may be incomplete, inaccurate, outdated, or subject to change, and Auxo Capital Advisors makes no representation or warranty, express or implied, as to its accuracy, completeness, or timeliness. Readers should conduct their own independent diligence and consult appropriate professional advisers before engaging any advisor, intermediary, investor, lender, acquirer, or other transaction counterparty.

Broker-dealer and securities disclosure

Auxo Capital Advisors is an affiliate of Weild & Co., Member FINRA | SIPC. Securities-related activities and securities transactions are conducted through Weild & Co.

Nothing contained on this page constitutes an offer to sell, an offer to purchase, or a solicitation of an offer to buy or sell any security, investment product, or financial instrument. Nothing on this page constitutes investment advice, a recommendation regarding any security, or a recommendation to enter into any transaction with the profiled firm or any other party.

Any securities transaction, capital-raising engagement, investment-banking engagement, or other securities-related activity involving Auxo Capital Advisors or Weild & Co. is subject to applicable regulatory requirements, internal review and approval, suitability and other applicable diligence requirements, and the terms of a separate written engagement or transaction agreement, as applicable.

Inclusion of a third-party firm in this directory does not imply affiliation with, sponsorship by, endorsement by, or any other relationship with Auxo Capital Advisors or Weild & Co. unless expressly stated otherwise.